Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study

References

• SazdanovicP, JankovicSM, KosticM, DimitrijevicA, StefanovicS. Pharmacokinetics of linezolid in critically ill patients. Expert Opin Drug Met. 2016;12(6):595–600. doi:10.1517/17425255.2016.1170807
   PubMed Web of Science ®Google Scholar
• LiuJ, GaoYH, WangXB, et al. Culture-positive spontaneous ascitic infection in patients with acute decompensated cirrhosis: multidrug-resistant pathogens and antibiotic strategies. Yonsei Med J. 2020;61(2):145–153. doi:10.3349/ymj.2020.61.2.14531997623
   PubMed Web of Science ®Google Scholar
• Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Ann NY Acad Sci. 2011;1222:49-54. doi:10.1111/j.1749-6632.2011.05962.x
   Google Scholar
• ZhouYL, ChenHT, HeHC, et al. Increased Enterococcus faecalis infection is associated with clinically active Crohn disease. Medicine. 2016;95(39):e5019. doi:10.1097/MD.000000000000501927684872
   PubMed Web of Science ®Google Scholar
• OuyangW, XueH, ChenY, et al. Clinical characteristics and antimicrobial patterns in complicated intra-abdominal infections: a 6-year epidemiological study in southern China. Int J Antimicrob Ag. 2016;47(3):210–216. doi:10.1016/j.ijantimicag.2015.12.019
   PubMed Web of Science ®Google Scholar
• LiuZH, LiJY, LiuHY, et al. The intestinal microbiota associated with cardiac valve calcification differs from that of coronary artery disease. Atherosclerosis. 2019;284:121–128. doi:10.1016/j.atherosclerosis.2018.11.03830897381
   PubMed Web of Science ®Google Scholar
• ChenJY, YiM, YaoSL, ZhangXP. Propofol target-controlled infusion modeling in rabbits: pharmacokinetic and pharmacodynamic analysis. J Huazhong U Sci-Med. 2016;36(3):428–433. doi:10.1007/s11596-016-1604-9
   Google Scholar
• DongH, XieJ, ChenL, et al. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients. Int J Infect Dis. 2014;22:35–40. doi:10.1016/j.ijid.2014.01.01624603161
   PubMed Web of Science ®Google Scholar
• LiQH, WenJ, YuKT, et al. Aloe-emodin induces apoptosis in human oral squamous cell carcinoma SCC15 cells. BMC Complement Altern Med. 2018:18. doi:10.1186/s12906-018-2353-z.29343256
   PubMed Web of Science ®Google Scholar
• Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Ch. 2010;54(11): 4605-4610. doi:10.1128/aac.00177-10
   Google Scholar
• RichardsGA, BrinkAJ. Therapeutic drug monitoring: linezolid too? Crit Care. 2014;18(5):525. doi:10.1186/s13054-014-0525-x25673559
   PubMed Web of Science ®Google Scholar
• ZollerM, MaierB, HornussC, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014;18(4):R148. doi:10.1186/cc1398425011656
   PubMed Web of Science ®Google Scholar
• RogerC, MullerL, WallisSC, et al. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemoth. 2016;71(2):464–470. doi:10.1093/jac/dkv349
   PubMed Web of Science ®Google Scholar
• TaubertM, ZollerM, MaierB, et al. Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients. Antimicrob Agents Ch. 2016;60(9):5254–5261. doi:10.1128/AAC.00356-16
   PubMed Web of Science ®Google Scholar
• IdeT, TakesueY, IkawaK, et al. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy. Int J Antimicrob Ag. 2018;51(5):745–751. doi:10.1016/j.ijantimicag.2018.01.021
   Web of Science ®Google Scholar
• BarrasaH, SoraluceA, UsónE, et al. Impact of augmented renal clearance on the pharmacokinetics of linezolid: advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. Int J Iect Dis. 2020;93:329–338. doi:10.1016/j.ijid.2020.02.044
   PubMed Web of Science ®Google Scholar
• BarrasaH, SoraluceA, IslaA, et al. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: influence of residual renal function on PK/PD target attainment. J Crit Care. 2019;50:69–76. doi:10.1016/j.jcrc.2018.11.01630496913
   PubMed Web of Science ®Google Scholar
• YangM, ZhangJ, ChenY, et al. Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis. Future Microbiol. 2017;12:39–50. doi:10.2217/fmb-2016-014027922745
   PubMed Web of Science ®Google Scholar
• MohriJ, KatadaC, UedaM, et al. Predisposing factors for chemotherapy-induced nephrotoxicity in patients with advanced esophageal cancer who received combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil. J Trans Int Med. 2018;6(1):32–37. doi:10.2478/jtim-2018-0007
   Web of Science ®Google Scholar
• OwenEJ, GibsonGA, BuckmanSA. Pharmacokinetics and pharmacodynamics of antimicrobials in critically ill patients. Surg Infect. 2018;19(2):155–162. doi:10.1089/sur.2017.262
   Web of Science ®Google Scholar
• CockcroftDW, GaultMH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi:10.1159/0001805801244564
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Bioanalytical method validation guidance for industry; 5 2018. Available from: https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 422, 2021.
   Google Scholar
• CometsE, BrendelK, MentréF. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Meth Prog Bio. 2008;90(2):154–166. doi:10.1016/j.cmpb.2007.12.002
   PubMed Web of Science ®Google Scholar
• KeizerRJ, KarlssonMO, HookerA. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT: Pharm Sys Pharm. 2013;2(6):e50. doi:10.1038/psp.2013.24
   Google Scholar
• De PascaleG, FortunaS, TumbarelloM, et al. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intens Care Med. 2015;41(1):103–110. doi:10.1007/s00134-014-3550-y
   PubMed Web of Science ®Google Scholar
• TaubertM, ZanderJ, FrechenS, et al. Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens. J Antimicrob Chemoth. 2017;72(8):2304–2310. doi:10.1093/jac/dkx149
   PubMed Web of Science ®Google Scholar
• RaynerCR, ForrestA, MeagherAK, BirminghamMC, SchentagJJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411–1423. doi:10.2165/00003088-200342150-0000714674791
   PubMed Web of Science ®Google Scholar
• ChoiGW, LeeJY, ChangMJ, et al. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases. Basic Clin Pharmacol Toxicol. 2019;124(2):228–234. doi:10.1111/bcpt.1312330171804
   PubMed Web of Science ®Google Scholar
• MatsumotoK, ShigemiA, TakeshitaA, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Ag. 2014;44(3):242–247. doi:10.1016/j.ijantimicag.2014.05.010
   PubMed Web of Science ®Google Scholar
• MinichmayrIK, SchaeftleinA, KutiJL, ZeitlingerM, KloftC. Clinical determinants of target non-attainment of linezolid in plasma and interstitial space fluid: a pooled population pharmacokinetic analysis with focus on critically ill patients. Clin Pharmacokinet. 2017;56(6):617–633. doi:10.1007/s40262-016-0463-727753002
   PubMed Web of Science ®Google Scholar
• VillaG, Di MaggioP, De GaudioAR, et al. Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review. Crit Care. 2016;20(1):374. doi:10.1186/s13054-016-1551-727863531
   PubMed Web of Science ®Google Scholar
• DongH, XieJ, WangT, et al. Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients. Int J Antimicrob Ag. 2016;48(3):259–264. doi:10.1016/j.ijantimicag.2016.05.009
   PubMed Web of Science ®Google Scholar
• TopperC, SteinbachCL, DornC, et al. Variable linezolid exposure in intensive care unit patients-possible role of drug-drug interactions. Ther Drug Monit. 2016;38(5):573–578. doi:10.1097/FTD.000000000000032427631464
   PubMed Web of Science ®Google Scholar
• PeaF, VialeP, CojuttiP, Del PinB, ZampariniE, FurlanutM. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemoth. 2012;67(8):2034–2042. doi:10.1093/jac/dks153
   PubMed Web of Science ®Google Scholar